Cg Oncology Inc's Customers Performance

Name: Cg Oncology Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

CGON

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


CGON's Source of Revenues		During the corresponding time, Cg Oncology Inc sequentially revenue grew by 6.83 %. While revenue at the Cg Oncology Inc 's corporate clients • List of CGON Customers

for the same period Cg Oncology Inc sequentially revenue grew by 6.83 %.

• List of CGON Customers

Cg Oncology Inc's Business Units


Commercial and Development Revenue	191.53 %	of total Revenue
License and Collaboration Revenue	2.07 %	of total Revenue
Member	193.6 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Cg Oncology Inc's Comment on Sales, Marketing and Customers

News about Cg Oncology Inc Contracts

Revolutionary Breakthrough: Cretostimogene Monotherapy Delivers Unprecedented 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Cretostimogene Monotherapy Shows Remarkable 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder CancerBladder cancer is a significant health concern globally, with non-muscle invasive bladder cancer (NMIBC) accounting for nearly three-quarters of all cases. While Bacillus Calmette-Guérin (BCG) immunotherapy has long been the standard treatment, a significant number of patients experience treatment failure or develop resistance. In such cases, finding an effective alternative becomes paramount. A recent study reveals promising results with cretostimogene monotherapy, demonstrating an exceptional 75.2% complete response rate in high-risk, BCG-unresponsive NMIBC patients.The...

CG Oncology Unveils Exciting Results of Cretostimogene-Pembrolizumab Combination at ASCO 2024, Potentially Evolving Cancer Treatment

The upcoming conference s highlight will be CG Oncology s presentation of the latest clinical trial results involving Cretostimogene and Pembrolizumab. Initial reports indicate that this combination therapy displays an unprecedented efficacy in combating various types of cancer. Such promising evidence has sparked excitement and high expectations within the medical community, as it holds the potential to revolutionize the landscape of cancer treatment.Cretostimogene, a novel viral immunotherapy, functions by stimulating the patient s immune system to target and eliminate cancer cells. This unique approach harnesses the power of the common cold virus as a delivery vehicle for activating the body s natural def...

CGON's Stock Performance relative to it's Customers

CGON's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Cg Oncology Inc	6,402.00	0.66	-186.75	142
SUBTOTAL	0.00	0.00	0.00	-

Sources: Cg Oncology Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Cg Oncology Inc’s corporate clients.
For your research, we’ve provided 9 tables on Cg Oncology Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.